IQVIA Holdings Inc. (NYSE:IQV) Shares Purchased by R Squared Ltd

Key Points

• R Squared Ltd increased its stake in IQVIA Holdings Inc. by 119.1% in the first quarter, bringing its total holdings to $707,000 and making it the company's 24th largest position.
• Multiple hedge funds modified their positions in IQVIA Holdings, with significant increases from Sowell Financial Services, Mather Group LLC, and Wealth Enhancement Advisory Services, indicating strong institutional interest in the company.
• IQVIA reported earnings of $2.81 per share for the last quarter, exceeding analyst expectations, and has a current price target consensus of $228.62 from analysts.

R Squared Ltd increased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 119.1% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,010 shares of the medical research company's stock after buying an additional 2,180 shares during the period. IQVIA comprises approximately 0.8% of R Squared Ltd's investment portfolio, making the stock its 24th biggest holding. R Squared Ltd's holdings in IQVIA were worth $707,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Continuum Advisory LLC lifted its stake in shares of IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after purchasing an additional 64 shares during the last quarter. Ballentine Partners LLC boosted its holdings in shares of IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock valued at $260,000 after buying an additional 69 shares in the last quarter. ST Germain D J Co. Inc. raised its stake in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares in the last quarter. Nemes Rush Group LLC lifted its position in IQVIA by 15.0% during the first quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock valued at $109,000 after acquiring an additional 81 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its stake in IQVIA by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 0.3%

Shares of NYSE:IQV traded up $0.52 during trading hours on Monday, reaching $182.97. The stock had a trading volume of 1,100,457 shares, compared to its average volume of 2,403,455. The stock has a market capitalization of $31.10 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 2.00 and a beta of 1.30. The firm's 50 day moving average is $162.11 and its 200-day moving average is $169.70. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.64 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently commented on the stock. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Evercore ISI boosted their price target on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research note on Wednesday, July 9th. Finally, JPMorgan Chase & Co. reduced their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research note on Monday, May 19th. Seven analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average target price of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.